Dyslipidemia: a prospective controlled randomized trial of intensive glycemic control in sepsis

Imagem de Miniatura
Arquivos
art_CAPPI_Dyslipidemia_a_prospective_controlled_randomized_trial_of_intensive_2012_eng.pdf (311.04 KB)
Citações na Scopus
27
Tipo de produção
article
Data de publicação
2012
Editora
SPRINGER
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
CURI, Rui
LOUREIRO, Tatiana C. A.
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
INTENSIVE CARE MEDICINE, v.38, n.4, p.634-641, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Metabolic disturbances are quite common in critically ill patients. Glycemic control appears to be an important adjuvant therapy in such patients. In addition, disorders of lipid metabolism are associated with worse prognoses. The purpose of this study was to investigate the effects that two different glycemic control protocols have on lipid profile and metabolism. We evaluated 63 patients hospitalized for severe sepsis or septic shock, over the first 72 h of intensive care. Patients were randomly allocated to receive conservative glycemic control (target range 140-180 mg/dl) or intensive glycemic control (target range 80-110 mg/dl). Serum levels of low-density lipoprotein, high-density lipoprotein, triglycerides, total cholesterol, free fatty acids, and oxidized low-density lipoprotein were determined. In both groups, serum levels of low-density lipoprotein, high-density lipoprotein, and total cholesterol were below normal, whereas those of free fatty acids, triglycerides, and oxidized low-density lipoprotein were above normal. At 4 h after admission, free fatty acid levels were higher in the conservative group than in the intensive group, progressively decreasing in both groups until hour 48 and continuing to decrease until hour 72 only in the intensive group. Oxidized low-density lipoprotein levels were elevated in both groups throughout the study period. Free fatty acids respond to intensive glycemic control and, because of their high toxicity, can be a therapeutic target in patients with sepsis.
Palavras-chave
Blood glucose, Sepsis, Fatty acids, Nonesterified, Lipids
URI
https://observatorio.fm.usp.br/handle/OPI/404
Referências
  1. Andersen SK, 2004, J LEUKOCYTE BIOL, V75, P413, DOI 10.1189/jlb.0503195
  2. Barlage S, 2009, INTENS CARE MED, V35, P1877, DOI 10.1007/s00134-009-1609-y
  3. Bone R C, 2009, Chest, V136, pe28
  4. Carantoni M, 1998, ARTERIOSCL THROM VAS, V18, P762
  5. Chaudhuri A, 2007, AM J CARDIOL, V100, P1614, DOI 10.1016/j.amjcard.2007.07.014
  6. Cominacini L, 2000, J BIOL CHEM, V275, P12633, DOI 10.1074/jbc.275.17.12633
  7. Cominacini L, 2001, J BIOL CHEM, V276, P13750
  8. Cury-Boaventura MF, 2006, LIFE SCI, V78, P1448, DOI 10.1016/j.lfs.2005.07.038
  9. Cury-Boaventura MF, 2006, JPEN-PARENTER ENTER, V30, P115, DOI 10.1177/0148607106030002115
  10. Ficker ES, 2010, ATHEROSCLEROSIS, V212, P230, DOI 10.1016/j.atherosclerosis.2010.04.030
  11. Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625
  12. Gordon BR, 1996, CRIT CARE MED, V24, P584, DOI 10.1097/00003246-199604000-00006
  13. Hatanaka E, 2006, FREE RADICAL BIO MED, V41, P1124, DOI 10.1016/j.freeadbiomed.2006.06.014
  14. Ling WH, 1997, J CLIN INVEST, V100, P244, DOI 10.1172/JCI119528
  15. Luangrath V, 2008, ARTERIOSCL THROM VAS, V28, P1290, DOI 10.1161/ATVBAHA.107.161653
  16. Manzella D, 2001, J CLIN ENDOCR METAB, V86, P2769, DOI 10.1210/jc.86.6.2769
  17. McCowen KC, 2001, CRIT CARE CLIN, V17, P107, DOI 10.1016/S0749-0704(05)70154-8
  18. Mesotten D, 2004, J CLIN ENDOCR METAB, V89, P219, DOI 10.1210/jc.2003-030760
  19. Miles J M, 1993, Curr Opin Gen Surg, P78
  20. MIZOCK BA, 1995, AM J MED, V98, P75, DOI 10.1016/S0002-9343(99)80083-7
  21. Navab M, 2000, J LIPID RES, V41, P1481
  22. Navab M, 1998, CURR OPIN LIPIDOL, V9, P449
  23. Nogueira AC, 2008, SHOCK, V29, P342
  24. Norata GD, 2002, NUTR METAB CARDIOVAS, V12, P297
  25. OLIVER MF, 1994, LANCET, V343, P155
  26. Paolisso G, 2000, AM J CLIN NUTR, V72, P723
  27. Pittet YK, 2010, INTENS CARE MED, V36, P289, DOI 10.1007/s00134-009-1689-8
  28. RUSSELL RO, 1976, CIRCULATION, V53, P207
  29. Schulz KF, 2010, ANN INTERN MED, V152, P726, DOI 10.1059/0003-4819-152-11-201006010-00232
  30. Scott JF, 1999, STROKE, V30, P793
  31. Soriano FG, 2006, CRIT CARE MED, V34, P1073, DOI 10.1097/01.CCM.0000206470.47721.8D
  32. Steinberg D, 1997, CIRCULATION, V95, P1062
  33. THOMAS JP, 1994, ARCH BIOCHEM BIOPHYS, V315, P244, DOI 10.1006/abbi.1994.1496
  34. Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300
  35. Vincent JL, 2000, ACTA CLIN BELG, V55, P79
  36. VOERMAN HJ, 1992, METABOLISM, V41, P934, DOI 10.1016/0026-0495(92)90117-S
  37. Wang HE, 2007, CRIT CARE MED, V35, P1928, DOI 10.1097/01.CCM.0000277043.85378.C1
  38. Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359
  39. Wendel M, 2007, INTENS CARE MED, V33, P25, DOI 10.1007/s00134-006-0433-x
  40. Zuurbier CJ, 2008, BRIT J ANAESTH, V100, P442, DOI 10.1093/bja/aen018

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/51